Healthcare Equipment and Supplies
Company Overview of Asuragen, Inc.
Asuragen, Inc., a molecular diagnostics company, provides patient management solutions in oncology and genetic disorders. The company discovers, develops, and commercializes diagnostic products for use in clinical laboratories and bio/pharma partners’ diagnostic needs. It offers diagnostic products and services, which include AmplideX FMR1 PCR reagents operates as a research tools for the detection of CGG repeats in the fragile X mental retardation (FMR1) gene; AmplideX FMR1 mPCR reagents that employ an PCR-only approach for the detection of methylation status in the FMR1 gene; AmplideX FMR1 Controls, which are mixtures of genomic DNA containing multiple alleles; Analyte specific reagents; a...
2150 Woodward Street
Austin, TX 78744
Founded in 2005
Key Executives for Asuragen, Inc.
Chief Executive Officer and President
Chief Financial Officer and Senior Vice President of Corporate Development
Senior Vice President of Operations
Senior Director of Clinical Affairs, Regulatory and Quality
Compensation as of Fiscal Year 2015.
Asuragen, Inc. Key Developments
Asuragen, Inc. to Collaborate with Illumina, Inc. on Companion Diagnostics Development
Sep 9 15
Asuragen, Inc. announced that it had entered into a collaboration agreement with Illumina, Inc. that establishes a framework for the development and commercialization of sequencing-based companion diagnostics in partnership with biotech and pharmaceutical companies. Asuragen will leverage its Quantidex NGS product platform for development of customized companion diagnostics for its biotech and pharma partners on the Illumina MiSeqDx instrument. Asuragen’s recently launched Quantidex Pan Cancer Kit demonstrates its optimized NGS system that unifies pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification, using reagents provided in a single kit. In addition, it integrates Asuragen’s analytics and reporting suite, the Quantidex Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels.
Asuragen, Inc. Announces the Launch of the Quantidex™ Pan Cancer Kit
Jul 8 15
Asuragen, Inc. announced the launch of the Quantidex™ Pan Cancer Kit. This next-generation sequencing (NGS) oncology panel offers a comprehensive workflow solution that integrates reagents, controls, and a novel bioinformatics suite for the sequencing of 21 genes relevant to a diverse set of human cancers. The technology builds upon Asuragen’s extensive experience in the NGS space and is optimized for the reliable interrogation of difficult sample types, such as formalin-fixed paraffin embedded (FFPE) and fine-needle aspiration (FNA) tissues. Incorporating a modular workflow design that can expedite content expansion, this approach includes the assimilation of both DNA and RNA targets, and provides a complete targeted NGS solution for laboratories wishing to adopt NGS. Although NGS offers advantages for sample multiplexing, high analytical sensitivity, and the ability to profile a large number of potentially clinically-actionable biomarkers in a single test, the complexities of incorporating an NGS workflow pose a barrier for many laboratories to overcome. The Quantidex™ Pan Cancer Kit provides a streamlined wet-bench protocol and companion “push-button” analysis software that facilitates rapid training and implementation, even for laboratories with little to no NGS experience or informatics infrastructure. In addition, the product unifies pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification using reagents provided in a single kit.
Asuragen, Inc. Launches the Quantidex DNA to Improve the Accuracy of Next-Generation Sequencing
Nov 11 14
Asuragen, Inc. announced the launch of the Quantidex DNA Assay at the Association for Molecular Pathology (AMP) Annual Meeting in National Harbor, MD. This product quantifies absolute copy numbers of genomic DNA, flags PCR inhibitors from the sample, and reports functional DNA quality from challenging specimens such as FFPE tumor biopsies using the QFI Score to increase the reliability and accuracy of next-generation sequencing (NGS) assays. The Quantidex DNA assay provides the QFI Score, which is the percentage of amplifiable DNA in a sample, and the number of amplifiable DNA copies to help guide inputs into NGS target enrichment to optimally balance DNA consumption with data quality. This information can guard against failed NGS runs, reduce the number of erroneous variant calls, and minimize the burden of confirmation testing. The assay also flags PCR inhibitors in the sample and creates opportunities to salvage such samples through a subsequent clean-up step prior to further processing. Finally, the assay procedure offers a simple and convenient workflow with pre-diluted and ready to use standards for ease of use and high reproducibility from laboratory-to-laboratory. The Quantidex DNA Assay has been evaluated with >2000 FFPE and FNA tumor biopsy samples and utilized in four peer-reviewed publications to date.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|